Compare · NVO vs OKUR
NVO vs OKUR
Side-by-side comparison of Novo Nordisk A/S (NVO) and OnKure Therapeutics Inc. (OKUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and OKUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 1105.3x OKUR ($169.7M).
- Over the past year, NVO is down 41.7% and OKUR is up 45.8% - OKUR leads by 87.5 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 1 for OKUR).
- NVO has more recent analyst coverage (25 ratings vs 3 for OKUR).
- Company
- Novo Nordisk A/S
- OnKure Therapeutics Inc.
- Price
- $42.01-2.10%
- $4.20+0.48%
- Market cap
- $187.53B
- $169.7M
- 1M return
- -5.38%
- -8.50%
- 1Y return
- -41.69%
- +45.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 1
- Recent ratings
- 25
- 3
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest OKUR
- SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.
- OnKure Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by OnKure Therapeutics Inc.
- OnKure Therapeutics Reports First Quarter 2026 Financial Results
- SEC Form EFFECT filed by OnKure Therapeutics Inc.
- SEC Form S-3 filed by OnKure Therapeutics Inc.
- SEC Form DEFA14A filed by OnKure Therapeutics Inc.
- SEC Form DEF 14A filed by OnKure Therapeutics Inc.
- SEC Form 3 filed by new insider Ai Biotechnology Llc
- SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.